Clinical Trial Update: A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating RC48-ADC combined with JS001 as perioperative treatment for muscle-invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• JS001 (PD-1 inhibitor)
• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Muscle Invasive Bladder Carcinoma | Phase 2 | Status: UNKNOWN